Chronic lymphocytic leukemia research studies
• Relapsed refractory (previously treated)
• Front line (previously untreated)
• Deletion 17p (del 17p)
Call 1-855-IBRUTINIB (1-855-427-8846) for more information, or choose a
trial below or click here to learn which treatment option may be best for you
The information provided herein may contain references to ibrutinib or a use of ibrutinib which has not been approved by any regulatory agency. Providing this information should not be construed as recommending the use of ibrutinib for uses which have not been approved by any regulatory agency. The safety and efficacy of the investigational use of ibrutinib has not been determined. There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency. For additional information, you may visit www.clinicaltrials.gov. For products approved by any regulatory agency please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product for its approved indications.